

ACURA PHARMACEUTICALS, INC  
Form 8-K  
June 02, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

June 2, 2008  
Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

**State of New York**  
(State of Other  
Jurisdiction  
of Incorporation)

**1-10113**  
(Commission File  
Number)

**11-0853640**  
(I.R.S. Employer  
Identification Number)

**616 N. North Court, Suite 120  
Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)

**(847) 705-7709**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))

**Item 8.01 Other Events**

On June 2, 2008 Acura Pharmaceuticals, Inc. (“Acura”) issued the attached press release being furnished as Exhibit 99.1, announcing that clinical evaluation is now permitted under an active Investigational New Drug application for a certain opioid analgesic product candidate using Aversion® technology, previously licensed by Acura to King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals, Inc.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number**

**Description**

99.1

Press Release of the Registrant dated June 2, 2008.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens

---

Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: June 2, 2008

---

**EXHIBIT INDEX**

**Exhibit Number**

**Description**

99.1

Press Release of the Registrant dated June 2, 2008.

---